We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Study on the method to avoid infusion-site adverse events following chemotherapeutic treatment with epirubicin and fosaprepitant using immortalized human umbilical vein endothelial cells.
- Authors
Yamasaki, Miho; Oda, Keisuke; Ichinose, Takashi; Mizuguchi, Marie; Tominaga, Shoko; Omoda, Kei; Mori, Nobuhiro; Maeda, Yorinobu; Nishida, Toshihiro; Murakami, Teruo
- Abstract
The combination of intravenous Proemend® containing fosaprepitant meglumine, a prodrug for fosaprepitant (FAP), and Tween 80 and chemotherapy with anthracyclines, such as epirubicin (EPI), can cause infusion-site adverse events in clinical practice. In immortalized human umbilical vein endothelial (HUEhT-1) cells, the cytotoxic effects of FAP, EPI, diluted Proemend with culture medium and Tween 80 alone, and a combination of FAP and EPI, were evaluated using the WST-1 cell viability assay. FAP, EPI and diluted Proemend exhibited cytotoxicity in a concentration-dependent manner and marked synergic cytotoxicity was observed between FAP and EPI. The washing of the cell surface following incubation with diluted Proemend containing FAP and Tween-80 eliminated the synergic cytotoxicity of EPI applied thereafter. These results indicated that washing of the infusion-site vascular tissue following intravenous Proemend administration via intravenous tube flushing with an efficient amount of saline may reduce the infusion-site adverse events, which are caused by the combined use of FAP and EPI.
- Subjects
UMBILICAL veins; ENDOTHELIAL cells; EPIRUBICIN; CANCER chemotherapy; INTRAVENOUS therapy
- Publication
Oncology Letters, 2022, Vol 24, Issue 5, pN.PAG
- ISSN
1792-1074
- Publication type
Article
- DOI
10.3892/ol.2022.13506